Since 2021, Philips Respironics has been embroiled in the ongoing recall of millions of breathing devices and ventilators used to treat sleep apnea.
On January 25th, 2024, Philips Respironics made a strategic announcement, discontinuing 19 sleep and respiratory products in the United States, redirecting its focus towards the sale of consumables and accessories, including masks.
Subsequently, on January 29th, 2024, Philips Respironics announced that it would halt sales of all of its breathing machines in the United States after reaching a settlement with the Food and Drug Administration over continuing problems with the devices.
Philips Respironics will not sell new CPAP or BiPAP sleep therapy devices or other respiratory care devices in the US until the relevant requirements of the consent decree are met, which includes a roadmap of defined actions, milestones, and deliverables. CEO Roy Jakobs from Philips said, as a general indication, it on average takes between five and seven years to comply with consent decrees in the medical equipment industry.
Despite these regulatory challenges, Philips Respironics will continue to service existing sleep and respiratory care devices for healthcare providers and patients in the US, while also supplying accessories, consumables, and replacement parts. Additionally, the company would continue to sell its products in other countries.
